Case Study

B-cell Chronic Lymphocytic Leukemia is Complicated by Autoimmune Hemolytic Anemia and Anti-phospholipid Syndrome

Kazuhiko Ikeda^{1),2)}, Tsutomu Shichishima²⁾, Tokuo Yui¹⁾,
Atsushi Otake¹⁾, Kazuyoshi Sakai¹⁾, Hideyoshi Noji²⁾,
Naoya Nakamura³⁾, Masafumi Abe³⁾ and Yukio Maruyama²⁾

We describe a rare case of a 68-year-old man with B-cell chronic lymphocytic leukemia (B-CLL) who developed autoimmune hemolytic anemia (AIHA) and anti-phospholipid syndrome (APS). On admission, he was diagnosed as having B-CLL and AIHA on the basis of CD5-positive B-lymphocytes infiltrated into his bone marrow and a positive Coombs test, respectively. Although the symptoms of B-CLL and AIHA were improved by chemotherapy, he developed deep-vein thrombosis, which was probably caused by a lupus anticoagulant. It was interesting that the thrombosis due to APS occurred following a decrease of hemolysis from AIHA after intensive chemotherapy.

Key words B-cell chronic lymphocytic leukemia, autoimmune hemolytic anemia, anti-phospholipid syndrome, lupus anticoagulant, deep-vein thrombosis

INTRODUCTION

Autoimmune diseases are closely associated with B-cell chronic lymphocytic leukemia (B-CLL)¹⁻³ and other lymphoproliferative diseases^{4,5}. Patients with B-CLL often develop autoimmune hemolytic anemia (AIHA)^{1-3,6-9}. However, there are only a few reported cases of B-CLL or other lymphoproliferative diseases in which the patients have both Coombs and anti-phospholipid antibodies^{10,11}. Here, we describe a case of B-CLL with AIHA and deep-vein thrombosis, probably due to lupus anticoagulant.

CASE REPORT

A 68-year-old man, with no history of throm-

boembolism or heart disease, was admitted to our hospital because of palpitations on March 25, 1999. On admission, no surface lymphadenopathy was seen, but a computed tomography (CT) scan examination of his abdomen showed hepatosplenomegaly and multiple para-aortic lymphadenopathy. Although premature ventricular contractions were observed on an electrocardiogram, findings by ultrasonic cardiography were within normal limits.

Hematological examination revealed a Hb of 6.1 g/dl, RBC of $148 \times 10^4/\mu\text{l}$, hematocrit 18.4%, MCV 124.1 fl, and reticulocyte count $4.3 \times 10^4/\mu\text{l}$ ($n: 3.0-10.0 \times 10^4/\mu\text{l}$), indicating macrocytic anemia. His WBC was $5.5 \times 10^3/\mu\text{l}$ with a lymphocyte count of $3.2 \times 10^3/\mu\text{l}$, platelet count $17.1 \times 10^4/\mu\text{l}$, prothrombin time 71%, thrombin time 54%, and activated partial thromboplastin time of 39.6 seconds. A biochemical examination showed serum lactate dehydrogenase at 1,035 IU/l, indirect bilirubin 3.50 mg/dl, haptoglobin 0 g/l, and a serum protein concentration of 5.5 g/dl with hypogammaglobulinemia 0.56 g/dl.

The result of immunoelectrophoresis of urine, but not that of serum, revealed κ -type Bence Jones proteins. Renal function test results, including serum creatinine and urea nitrogen, were normal.

Received: Nov 2, 2001

Revised: Apr 15, 2002

Accepted: May 2, 2002

¹⁾Department of Internal Medicine, Fukushima Prefectural Kitakata Hospital, Kitakata; ²⁾First Department of Internal Medicine; and ³⁾First Department of Pathology, Fukushima Medical University, Fukushima, Japan

Address correspondence and reprint request to Yukio Maruyama, First Department of Internal Medicine, Fukushima Medical University, 1 Hikariga-oka, Fukushima 960-1295, Japan

Fig. 1. Morphological appearance of these cells is compatible with B-cell chronic lymphocytic leukemia. A : May-Giemsa-stained film from bone marrow (100 $\times$) indicates a numerous mononuclear cells in the aspiration smear of bone marrow. B : May-Giemsa-stained film from bone marrow (1000 $\times$) indicates a monotonous proliferation of small mature lymphocytes with condensed chromatin. Nuclear irregularities and nucleoli are inconspicuous.

C-reactive protein was 0.9 mg/dl. IgG antibody in a direct Coombs test was strongly positive (1 : 64) and his cold agglutinin titer was low. Antinuclear antibody, anti-DNA antibody, anti-Sm antibody, antineutrophilic cytoplasmic antibody, rheumatoid factor, and anti-platelet antibody were negative. Bone marrow aspirate demonstrated hypercellularity with 76.8% small lymphoid cells (Fig. 1A and B), which was also found in a bone marrow biopsy. Flow cytometry of bone marrow and peripheral blood mononuclear cells showed, respectively, that 53.1% and 50.5% were CD5⁺, 93.7% and 60.2% CD19⁺, 47.4% and 36.3% CD21⁺, 51.8% and 44.3% CD23⁺, 93.1% and 95.7% CD43⁺, and 95.3% and 83% HLA-DR⁺. Also, surface IgG⁺, IgA⁺, IgM⁺, and κ - and λ -light chain⁺ cells were 12%, 0%, 1%, 14% and 1%, respectively, of bone marrow mononuclear cells.

A chromosomal analysis, without the addition of mitogen to the bone marrow cells, showed 46, XY (20/20 cells). A rearranged band in the immunoglobulin heavy-chain gene was detected by Southern blot analysis of the bone marrow specimen, while expression of cyclin D1 measured by fluorescence *in situ* hybridization was not increased in this patient compared to healthy volunteers. Based on the findings, the patient was diagnosed as having B-CLL, according to the World Health Organization classification of neoplastic diseases of hematopoietic and lymphoid tissues¹², along with AIHA. The clinical stage was C in accordance with the criteria of the clinical staging system of CLL developed by Binet¹³.

The patient's clinical course is summarized in Fig. 2. Although his anemia improved slightly from 60 mg/day of prednisolone starting in April, 1999,

he developed a fever higher than 39°C and developed pancytopenia. On May 12, his Hb was 7.6 g/dl, WBC $1.2 \times 10^3/\mu\text{l}$ with 6% granulocytes and 94% lymphocytes, and his platelet count was $13.0 \times 10^4/\mu\text{l}$. Bone marrow aspirate taken on May 20 showed remarkable infiltration, with 85.4% leukemic cells, 52% of which were CD5⁺, 90% CD19⁺, and 65.3% CD23⁺. A CT scan showed systemic progression of lymphadenopathy and hepatosplenomegaly.

Starting on May 24, 1999, the patient was treated with two courses of pirarubicin, cyclophosphamide, vincristine, and prednisolone. After the chemotherapy, his lymphadenopathy and hepatosplenomegaly improved markedly. On June 18, 1999, hematological parameters were: WBC of $6.9 \times 10^3/\mu\text{l}$, Hb of 8.4 g/dl, and a platelet count of $18.0 \times 10^4/\mu\text{l}$. A bone marrow aspirate showed 67.4% leukemic cells, 23.4% myeloid cells, and 8.0% erythroblasts with no morphological abnormalities of myeloid, erythroid and megakaryocytic lineages or hemophagocytosis. A chromosomal analysis of bone marrow cells showed 46, XY (20/20 cells). The titer of Coombs antibody (IgG) also dropped (1 : 2). However, further chemotherapy could not be administered because of interstitial pneumonia following candidiasis.

On June 23, 1999, the patient suddenly complained of swelling, edema and pain in his right leg, and his platelet count had decreased to $11.7 \times 10^4/\mu\text{l}$. As a cause of thrombocytopenia there were no findings that suggested myelodysplastic syndrome, aplastic anemia, or immune thrombocytopenia in his bone marrow. In addition, the concentrations of plasma fibrinogen degradation products, thrombin-

Fig. 2. Course of clinical manifestations, hematological findings, and treatment. ¶ Clinical manifestations: IP, interstitial pneumonia; DVT, deep-vein thrombosis; and DIC, disseminated intravascular coagulation. \$ Bone marrow: NCC, nucleated-cell count ($10^4/\mu\text{l}$). *Peripheral blood: WBC ($10^3/\mu\text{l}$); concentration of Hb (g/dl); platelet count ($10^4/\mu\text{l}$). †Treatment: PSL, prednisolone (mg/day); mPSL, methylprednisolone (1000 mg/day); Cx, chemotherapy with cyclophosphamide, pirarubicin, vincristine and PSL; G-CSF, granulocyte colony-stimulating factor; FFP, frozen fresh plasma.

antithrombin III complex, and D-dimer increased to $80 \mu\text{g/ml}$ ($n < 10$), $60 \mu\text{g/ml}$ ($n < 3.0$), and $470 \mu\text{g/ml}$ ($n < 0.5$), respectively. He was diagnosed with deep-vein thrombosis due to anti-phospholipid syndrome (APS) because of the positive finding of lupus anticoagulant, although the concentration of anti-cardiolipin β_2 GP I antibody was 3.2 U/ml ($n < 3.5$). The autoantibodies described above were assessed again and were also negative.

Based on the diagnosis of APS, 15,000 units/day of heparin were administered for one month with no improvement of deep-vein thrombosis in his leg following disseminated intravascular coagulation. On July 23, 1999, he died of respiratory failure due to progression of interstitial pneumonia. No autopsy was performed.

DISCUSSION

Although the peripheral blood lymphocyte count in the our patient was below $5.0 \times 10^3/\mu\text{l}$, a criterion of the National Cancer Institution Working Group⁸, he was diagnosed with B-CLL based on peripheral blood lymphocytes that had the same surface phenotype, as determined by flow cytometry, with cells infiltrating the bone marrow, suggesting

B-CLL or B-cell small lymphocytic lymphoma (B-SLL). In fact, it is thought that B-CLL is the same disorder as B-SLL as reflected in some recent classifications^{12,14}.

A normal counterpart of the abnormal cells in B-CLL is a subpopulation of mature CD5-positive B-lymphocytes, differentiated to producing autoantibodies and located in the mantle zone of the lymphoid follicle and in the peripheral blood in small numbers^{1,2}. The number of these CD5-positive B-lymphocytes increases in autoimmune diseases although it is not defined whether autoantibody-producing cells belong to the CD5-positive lymphocytes¹. In the present patient, CD5-positive B-lymphocytes increased at the time of onset of AIHA and decreased as AIHA improved. This fact suggests the possibility that CD5-positive B-lymphocytes contributed to the occurrence of AIHA.

Patients with lymphoproliferative disorders often develop autoimmune diseases^{4,5}. 7 to 25% of B-CLL patients^{3,6,7} and 8% of APS patients¹⁵ develop AIHA, but reports of lymphoproliferative diseases with anti-phospholipid antibodies are rare. To our knowledge, 19 cases of lymphoproliferative diseases, including B-CLL with anti-phospholipid antibodies, have been reported^{10,11,16-18}. Coombs tests

were positive in three of the 19 cases reported: one with B-CLL¹⁰ and two with splenic marginal zone cell lymphoma (SMZCL)¹¹. One case with B-CLL developed hemolytic anemia and phlebitis¹⁰, and two cases with SMZCL had AIHA without thrombosis¹¹. One reported case with B-CLL and another with SMZCL had lupus anticoagulant and IgM anti-cardiolipin antibody, and a further case with SMZCL had only lupus anticoagulant. The leukemic-B cells of the patient with B-CLL produced IgM λ , which reacts with anti-cardiolipin antibody, but not with anti-human IgG¹⁰. In patients with SMZCL, not only anti-phospholipid antibodies but also Coombs antibodies disappeared after treatments for lymphoma, suggesting that lymphoma cells probably produced these autoantibodies¹¹.

It is not clear why the hemolytic anemia improved slightly, but thrombosis progressed, after intensive chemotherapies in the present patient. Unfortunately, we did not examine for lupus anticoagulant before the intensive chemotherapy or the improvement of AIHA because there were no clinical signs suggesting APS. However, from his age and various coagulation tests, no genesis of thrombosis other than from APS was found in this patient. In addition, although antibodies to red cells from our patient belonged to the IgG subclass, we could not determine the Ig subclasses of lupus anticoagulants because the antibodies are generally found by coagulation tests^{19,20}, suggesting that the relationship between AIHA antibodies, anti-lupus antibodies, and B-CLL cells is unclear.

On the other hand, only two cases with lymphoproliferative diseases who developed thrombosis due to APS without AIHA have been reported^{16,17}. Lymphoplasmacytic lymphoma of the spleen was diagnosed in one of them¹⁶, who had lupus anticoagulant and developed a pulmonary embolism. The titer of lupus anticoagulant in this patient decreased after splenectomy. In the other patient, with diffuse large B-cell lymphoma (DLBCL) who had lupus anticoagulant but not anti-cardiolipin antibodies, thrombosis progressed despite intensive chemotherapies, but improved by administration of methylprednisolone and plasma exchange¹⁷. Our case also had only the lupus anticoagulant without anti-cardiolipin antibodies. It is possible that thromboses in patients with lymphoproliferative disorders and APS tend to be caused mainly by lupus anticoagulant. We should consider splenectomy and/or plasma exchange to treat throm-

bosis from APS-resistant to intensive chemotherapies against leukemia.

In conclusion, we described a rare case of B-CLL complicated by AIHA and APS with deep-vein thrombosis probably due to lupus anticoagulant. It was interesting that the thrombosis due to APS occurred following a decrease in hemolysis from AIHA after intensive chemotherapy.

REFERENCES

- 1 Caligaris-Cappio F. B-chronic lymphocytic leukemia: a malignancy of anti-self B cells. *Blood* 87: 2615-2620, 1999
- 2 Kipps TJ, Carson DA. Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. *Blood* 81: 2475-2487, 1993
- 3 Rozman C, Montserrat E: Chronic lymphocytic leukemia. *N Engl J Med* 333: 1052-1057, 1995
- 4 Abu-Shakura M, Gladman DD, Urowitz MB: Malignancy in systemic lupus erythematosus. *Arth Rheum* 39: 1050-1054, 1996
- 5 Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, Costa J, Decker JL, Chused TM: Increased risk of lymphoma in sicca syndrome. *Ann Intern Med* 89: 888-892, 1978
- 6 O'Brien S, Giglio A, Keating M: Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. *Blood* 1995; 85: 307-318.
- 7 Efremov DG, Ivanovski M, Burrone OR: The pathologic significance of the immunoglobulins expressed by chronic lymphocytic leukemia B-cells in the development of autoimmune hemolytic anemia. *Leuk Lymphoma* 28: 285-293, 1998
- 8 Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Schiffer CA, Oken MM, Keating MJ, Boldt DH, Kempin SJ, Foon KA: Guidelines for clinical protocols for Chronic Lymphocytic Leukemia: Recommendations of the National Cancer Institute-Sponsored Working Group. *Am J Hematol* 29: 152-163, 1988
- 9 Jonsson V, Svendsen B, Vorstrup S, Krarup C, Schmalbruch H, Thomsen K, Heegaard NH, Wiik A, Hansen MM: Multiple autoimmune manifestations in monoclonal gammopathy of undetermined significance and chronic lymphocytic leukemia. *Leukemia* 10: 327-332, 1996
- 10 Marriette X, Levy Y, Dubreuil ML, Intrator L, Danon F, Brouet JC: Characterization of a human monoclonal antibody directed to cardiolipin/ β 2 glycoprotein I produced by chronic lymphocytic leukaemia Bcells. *Clin Exp Immunol* 94: 385-390, 1993

- 11 Murakami H, Irisawa H, Saitoh T, Matsushima T, Tamura J, Sawamura M, Karasawa M, Hosomura Y, Kojima M: Immunological abnormalities in splenic marginal zone cell lymphoma. *Am J Hematol* 56 : 173–178, 1997
- 12 Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD: World Health Organization classification of the hematopoietic and lymphoid tissues : Report of the clinical advisory committee meeting-Airlie House, Virginia, November 1997. *J Clin Oncol* 17 : 3835–3849, 1999
- 13 Binet JL, Lepoprier M, Dighiero G, Charron D, D'Athis P, Vaugier G, Beral HM, Natali JC, Raphael M, Nizet B, Follezu JY. A clinical staging system for chronic lymphocytic leukemia : prognostic significance. *Cancer* 40 : 855–864, 1977
- 14 Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peters C, Falini B, Gatter KC : A revised European-American classification of lymphoid neoplasms : A proposal from the International Lymphoma Study Group. *Blood* 84 : 1361–1392, 1994
- 15 Lockshin MD, Sammaritano LR, Schwartzman : Validation of the Sapporo criteria for antiphospholipid syndrome. *Arth Rheum* 43 : 440–443, 2000
- 16 Ciaudo M, Horellou MH, Audouin J, De Carbonnieres C, Conard J, Samama M : Lupus anticoagulant associated with primary malignant lymphoplasmacytic lymphoma of the spleen : a report of four Patients. *Am J Hematol* 38 : 271–276, 1991
- 17 Keung YK, Cobos E, Meyerrose GE, Roberson GH. Progressive thrombosis after treatment of diffuse large cell non-Hodgkin's lymphoma and concomitant lupus anticoagulant. *Leuk Lymphoma* 20 : 341–345, 1996
- 18 McGuire D, Zeidman A, Mittelman M. Non-Hodgkin's lymphoma presenting with coagulopathy due to anti-phospholipid antibody syndrome. *Leuk Lymphoma* 26 : 193–196, 1997
- 19 Triplett DA, Barna LK, Unger GA. A hexagonal (II) phase phospholipids neutralization assay for lupus anticoagulant identification. *Thromb Haemost* 70 : 787–793, 1993
- 20 Roubey RAS. Antibodies to phospholipid-binding plasma proteins : a new view of lupus anticoagulant and other “antiphospholipid” autoantibodies. *Blood* 84 : 2854–2867, 1994